04.11.2019 • TopicsSphera

Sphera Solutions identified as a Leader for Chemicals Management in the Verdantix Green Quadrant EHS Software 2019

©Sphera Solutions
©Sphera Solutions

Sphera, the largest global provider of Integrated Risk Management software, has been named a Green Quadrant leader for Chemicals Management solution by Verdantix, an independent research and consulting firm, in the “EHS Software Benchmark: "Chemicals Management” report, which was released October 1, 2019.

The report stated that “Sphera is currently the only vendor among the 23 EHS [Environmental Health & Safety] software providers to provide end-to-end functionality for EHS, chemicals compliance and product life cycle assessment analysis.” According to senior EHS analyst, Sphera’s solution offers strong depth and breadth of Chemicals Management capabilities.



Download Full Verdantix - EHS Software Benchmark - Chemicals Management Report

Company

Sphera Solutions

8 Waldegrave Road
TW11 8GT Teddington

Company contact







Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • TopicsStrategy

Substances of Concern

The EU Chemicals Strategy for Sustainability (CSS) highlights the shift to a hazard-centric approach in EU chemical regulation, emphasizing 'Substance of Concern' over risk-based measures.

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.